Rocket Pharmaceuticals, Inc. stock is up 34.29% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November. In the last 8 Unusual Options Trades, there were 3 PUTs, 5 CALLs.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|12 Oct 18:38||20 Oct, 2023||22.50||580|
|13 Oct 15:11||20 Oct, 2023||17.50||3812|
|18 Oct 14:45||19 Apr, 2024||12.50||1|
|26 Oct 15:48||17 Nov, 2023||17.50||89|
|26 Oct 19:18||19 Apr, 2024||30.00||25|
|15 Nov 16:35||19 Jan, 2024||12.50||32|
|15 Nov 18:28||19 Jan, 2024||25.00||5351|
|30 Nov 15:10||19 Jan, 2024||30.00||0|
Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells. The company also has a clinical stage in vitro virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure.